An Engineered Hierarchical Hydrogel with Immune Responsiveness and Targeted Mitochondrial Transfer to Augmented Bone Regeneration.

Publisher: WILEY-VCH Country of Publication: Germany NLM ID: 101664569 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2198-3844 (Electronic) Linking ISSN: 21983844 NLM ISO Abbreviation: Adv Sci (Weinh) Subsets: MEDLINE

Original Publication: Weinheim : WILEY-VCH, [2014]-

Bone Regeneration*/immunology ; Bone Regeneration*/physiology ; Hydrogels* ; Mitochondria*/metabolism ; Mesenchymal Stem Cells*/immunology ; Mesenchymal Stem Cells*/metabolism; Animals ; Mice ; Tissue Engineering/methods

Coordinating the immune response and bioenergy metabolism in bone defect environments is essential for promoting bone regeneration. Mitochondria are important organelles that control internal balance and metabolism. Repairing dysfunctional mitochondria has been proposed as a therapeutic approach for disease intervention. Here, an engineered hierarchical hydrogel with immune responsiveness can adapt to the bone regeneration environment and mediate the targeted mitochondria transfer between cells. The continuous supply of mitochondria by macrophages can restore the mitochondrial bioenergy of bone marrow mesenchymal stem cells (BMSC). Fundamentally solving the problem of insufficient energy support of BMSCs caused by local inflammation during bone repair and regeneration. This discovery provides a new therapeutic strategy for promoting bone regeneration and repair, which has research value and practical application prospects in the treatment of various diseases caused by mitochondrial dysfunction.
(© 2024 The Author(s). Advanced Science published by Wiley‐VCH GmbH.)

Adv Sci (Weinh). 2024 Nov;11(42):e2406287. (PMID: 39258577)
Cell Metab. 2023 Feb 7;35(2):345-360.e7. (PMID: 36754021)
Biomaterials. 2022 Jul;286:121604. (PMID: 35667249)
Nat Rev Rheumatol. 2021 Oct;17(10):608-620. (PMID: 34480164)
Langmuir. 2014 Aug 19;30(32):9625-36. (PMID: 24754399)
Sci Adv. 2021 Oct;7(40):eabj0534. (PMID: 34586849)
Lancet Diabetes Endocrinol. 2019 Mar;7(3):221-230. (PMID: 30115599)
Sci Adv. 2021 Dec 10;7(50):eabj7857. (PMID: 34890238)
Biomacromolecules. 2022 Jan 10;23(1):303-315. (PMID: 34914360)
Biomaterials. 2015 Nov;68:42-53. (PMID: 26264645)
Nature. 2016 Jul 27;535(7613):551-5. (PMID: 27466127)
Cell Metab. 2021 Feb 2;33(2):283-299.e9. (PMID: 33400911)
Adv Sci (Weinh). 2023 Feb;10(4):e2204871. (PMID: 36507570)
J Cereb Blood Flow Metab. 2021 Apr;41(4):761-770. (PMID: 32501156)
J Control Release. 2022 Mar;343:89-106. (PMID: 35077740)
Adv Mater. 2022 Sep;34(36):e2202044. (PMID: 35785450)
Nat Cell Biol. 2020 Jan;22(1):7-17. (PMID: 31907409)
Cell. 1988 Mar 25;52(6):811-9. (PMID: 3349520)
Nat Biomed Eng. 2022 Oct;6(10):1167-1179. (PMID: 34980903)
Cell Prolif. 2022 Mar;55(3):e13191. (PMID: 35088483)
Sci Adv. 2022 Aug 19;8(33):eabp9245. (PMID: 35977014)
Endocr Rev. 2017 Jun 1;38(3):255-266. (PMID: 28472361)
Nat Biotechnol. 2013 Jun;31(6):553-6. (PMID: 23666011)
Nature. 2018 Oct;562(7725):133-139. (PMID: 30250253)
Stem Cells Dev. 2012 Mar 1;21(4):575-88. (PMID: 21615273)
Biomaterials. 2020 Jan;227:119552. (PMID: 31670079)
Trends Mol Med. 2020 Jan;26(1):89-104. (PMID: 31126872)
Stem Cell Res Ther. 2022 Feb 22;13(1):77. (PMID: 35193674)
Cell Death Dis. 2023 May 13;14(5):324. (PMID: 37173333)
Int J Oral Sci. 2019 Aug 19;11(3):23. (PMID: 31423011)
J Exp Clin Cancer Res. 2019 Jan 23;38(1):30. (PMID: 30674338)
Cell. 2023 Mar 16;186(6):1212-1229.e21. (PMID: 36827974)
Adv Mater. 2021 Aug;33(32):e2102044. (PMID: 34216408)
Nat Metab. 2023 Apr;5(4):546-562. (PMID: 37100996)
Signal Transduct Target Ther. 2021 Feb 16;6(1):65. (PMID: 33589598)
Adv Drug Deliv Rev. 2021 Jul;174:504-534. (PMID: 33991588)
Nat Nanotechnol. 2022 Jan;17(1):98-106. (PMID: 34795441)
Cell. 2021 Oct 14;184(21):5375-5390.e16. (PMID: 34562363)
Protein Cell. 2017 Jun;8(6):439-445. (PMID: 28271444)
Nat Commun. 2022 Sep 5;13(1):5211. (PMID: 36064711)
Mol Metab. 2022 Apr;58:101450. (PMID: 35121170)
Biomacromolecules. 2023 Jul 10;24(7):3345-3356. (PMID: 37380981)
Nat Med. 2019 Oct;25(10):1566-1575. (PMID: 31591594)
Nat Immunol. 2010 Oct;11(10):889-96. (PMID: 20856220)
Nat Biomed Eng. 2018 May;2(5):318-325. (PMID: 30936455)
Ageing Res Rev. 2020 Sep;62:101128. (PMID: 32712108)
Nat Rev Mol Cell Biol. 2020 Nov;21(11):696-711. (PMID: 32901139)

. 82271001 National Natural Science Foundation of China; 2021C03113 Zhejiang Provincial Key Research and Development Program of China; 2021KY194 Health Department of Zhejiang Province Fund; 2022KY872 Health Department of Zhejiang Province Fund; 82301018 National Outstanding Youth Science Fund Project of National Natural Science Foundation of China

Keywords: bioenergy metabolism; bone mesenchymal stem cells; bone regeneration; mitochondrial transfer

0 (Hydrogels)

Date Created: 20240911 Date Completed: 20241113 Latest Revision: 20241115

20250114

PMC11558138

10.1002/advs.202406287

39258577